Trovagene Inc (NASDAQ:TROV)

0.81
Delayed Data
As of Jun 15
 -0.025 / -2.99%
Today’s Change
0.79
Today|||52-Week Range
19.56
-78.05%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$17.7M

Company Description

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.

Contact Information

TrovaGene, Inc.
11055 Flintkote Avenue
San Diego California 92121
P:(858) 952-7570
Investor Relations:

Employees

Shareholders

Mutual fund holders0.00%
Individual stakeholders--
Other institutional--

Top Executives

Bill WelchPresident, CEO, CFO & Director
Mark ErlanderChief Scientific Officer
George SamuelVice President & General Counsel
Nick NelsonVice President-Strategy & Corporate Development